# @elilillyco on Instagram

- **Type:** Video
- **Original URL:** https://www.instagram.com/p/Dd6zvx9j1zK
- **Gondola URL:** https://gondola.cc/posts/71215678-elilillyco-instagram
- **Thumbnail:** https://img.gondola.cc/tr:w-,h-,fo-auto/postThumbnails/5c84e123f8.jpg
- **Posted:** 2026-09-30T18:00:02.000+00:00
- **Account Owner:** Eli Lilly and Company (@elilillyco) — https://gondola.cc/elilillyco

## Caption

Our investigational combination of a selective amylin agonist and GIP/GLP-1 receptor agonist showed promising results for adults living with both obesity and type 2 diabetes, including substantial weight loss and meaningful blood sugar reduction.

These results, announced at the European Association for the Study of Diabetes, matter because obesity and type 2 diabetes often share common biology. Potential treatments like this could offer real, meaningful benefit to people navigating both conditions. See our press release at the link in bio.

#EASD2026

## Stats

- **Views:** 5,043
- **Likes:** 140
- **Shares:** 0
- **Comments:** 18

## Tags

easd2026

---
Copyright (c) Gondola